acute-myeloid-leukemia

Documents about acute-myeloid-leukemia

• Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia#907159ClinicalTrials.gov
• Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies#859115ClinicalTrials.gov
• BCR::ABL1 e1a2 (p190)-Positive Myeloid Blast Neoplasm: Diagnostic Challenges in Distinguishing De Novo Acute Myeloid Leukemia From Previously Unrecognized Chronic Myeloid Leukemia in the Blast Phase.#613506NCBI PubMed Central
• Donor Bone Marrow Transplantation in Treating Patients With Hematologic Cancer#836349ClinicalTrials.gov
• Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia#995297ClinicalTrials.gov
• Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies#888432ClinicalTrials.gov
• Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)#849659ClinicalTrials.gov
• Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia#880914ClinicalTrials.gov
• Interest of a Therapeutic Follow-up of the Cytarabine in the Acute Myeloid Leukaemia: Is There Constitutional Biomarkers#813222ClinicalTrials.gov
• Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide#849515ClinicalTrials.gov
• Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia#889877ClinicalTrials.gov
• Observational Study of Iron Overload in Stem Cell Transplantation#897545ClinicalTrials.gov
• Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia#995650ClinicalTrials.gov
• DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AML#1008486ClinicalTrials.gov
• OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies#1047616ClinicalTrials.gov
• Targeting WNK1 Releases Differentiation Block in Acute Myeloid Leukemia#222319bioRxiv / medRxiv
• Gamma Delta T Cells in AML#901783ClinicalTrials.gov
• Retrospective, real‐life study of venetoclax plus azacitidine or low‐dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy#175708HAL (France)
• Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance#359884Gestión del Repositorio Documental de la Universidad de Salamanca
• Targeting systemic and tumor metabolic balances with ketogenic diets enhance efficacy of therapy in FLT3-ITD acute myeloid leukemia#445641HAL (France)
• Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)#805286ClinicalTrials.gov
• Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)#811208ClinicalTrials.gov
• Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)#895520ClinicalTrials.gov
• A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy#967616ClinicalTrials.gov
• Reduction of Cord Blood Transplantation Toxicity in Patients With Acute Myeloid Leukemia#995308ClinicalTrials.gov
• Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation#860672ClinicalTrials.gov
• Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies#992687ClinicalTrials.gov
• Data Sheet 1_Short-term mortality after intensive care admission in acute lymphoblastic versus predominantly acute myeloid leukemia: a retrospective cohort study using MIMIC-IV with eICU external replication.docx#635003Figshare
• Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin#803353ClinicalTrials.gov
• Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT#877059ClinicalTrials.gov
• Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse#837416ClinicalTrials.gov
• MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)#841952ClinicalTrials.gov
• the Efficacy and Safety of Total Myeloid Irradiation (TMI) in the Treatment of Adult Acute Lymphoblastic Leukemia#1046045ClinicalTrials.gov
• Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML#860266ClinicalTrials.gov
• A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia#876286ClinicalTrials.gov
• Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases#873076ClinicalTrials.gov
• Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/Refractory Leukemia#861890ClinicalTrials.gov
• Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care#901898ClinicalTrials.gov
• A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia#875995ClinicalTrials.gov
• Pilot Study Immunomonitoring Natural Killers Cells in Patients With Myeloid Malignancies Treated With Lenalidomide#442094ClinicalTrials.gov
• Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia#896480ClinicalTrials.gov
• SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS#877946ClinicalTrials.gov
• Efficiency of Antibacterial Prophylaxis in Azacitidine Treated Patients#184885ClinicalTrials.gov
• Pilot Study of Reduced Venetoclax Exposure#896653ClinicalTrials.gov
• Myelodysplastic Syndrome and Acute Myeloid Leukemia Related to PARP Inhibitors (MyeloRIB)#993941ClinicalTrials.gov
• Cladribine Venetoclax in Monocytic AML#1007988ClinicalTrials.gov
• MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies#904118ClinicalTrials.gov
• Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies#812791ClinicalTrials.gov
• Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)#812139ClinicalTrials.gov
• Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML#850534ClinicalTrials.gov